HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Thomas Schachner Johannes Bonatti Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schachner, T. Articles by Bonatti, J. Search for Related Content PubMed PubMed Citation Articles by Schachner, T. Articles by Bonatti, J. Related Collections Cardiac - pharmacology Related Article

Ann Thorac Surg 2005;79:2202
© 2005 The Society of Thoracic Surgeons

---

Correspondence

Reply

Department of Cardiac Surgery, Medical University Innsbruck, Innsbruck, Austria

(E-mail: thomas.schachner{at}uibk.ac.at).

To the Editor:

Subacute thrombosis of sirolimus (Rapamycin; AG Scientific, San Diego, CA) eluting coronary stents is reported in the 1% range, despite an aggressive treatment with aspirin and clopidogrel [1].

In their letter, Walpoth and colleagues pointed out an increased thrombosis rate in experimental Rapamycin-treated synthetic vascular grafts.

We reviewed our own data regarding thrombosis in experimental vein grafts, which were treated with perivascularly applied Rapamycin in a mouse model. Interestingly, thrombosed vein grafts (found after harvesting in apparently normal mice) were found only in 100 µg Rapamycin-treated vein grafts (n = 3/28 [11%]) and controls (n = 2/28 [7%]), whereas in 200 µg Rapamycin-treated vein grafts (n = 30) no thrombosed vein graft was found There was no significant difference in thrombosis rates between Rapamycin 100 µg or 200 µg treated grafts and controls. We additionally investigated mortality differences in these animals, because thrombosis of the carotid interposition graft might be one possible cause of death in this animal model.

Death occurred in 0 of 28 (0%) of 100 µg Rapamycin-treated vein grafts, and 1 of 28 (4%) of controls, whereas it occurred in 4 of 30 (13%) of 200 µg Rapamycin-treated vein grafts. There was no significant difference in death rates between Rapamycin 100 µg or 200 µg treated grafts and controls.

In our experience using a mouse model, Rapamycin did not increase thrombosis rates in experimental vein grafts. This might be due to the local perivascular application.

	References

Top References

 

1. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation Circulation 2004;109:1930-1932.[Abstract/Free Full Text]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Thomas Schachner Johannes Bonatti Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schachner, T. Articles by Bonatti, J. Search for Related Content PubMed PubMed Citation Articles by Schachner, T. Articles by Bonatti, J. Related Collections Cardiac - pharmacology Related Article